GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Mark Cuban’s Cost Plus Drug Co. and virtual care provider 9amHealth have partnered to offer obesity medications through a new program targeting self-insured employers. Under the partnership, 9amHealth ...

The Mark Cuban Cost Plus Drug Company has entered into a new partnership with the aim of making obesity medications ...

The companies are working together to make it easier for companies to offer health plans that include these medications.

Telehealth firm 9amHealth has partnered with billionaire entrepreneur Mark Cuban's Cost Plus Drug Company to offer U.S.

Health, a leader in complete cardiometabolic care, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), today ...

Please replace the release dated June 11, 2025 with the following corrected version due to multiple revisions.

Smart Meter, a pioneer in cellular-enabled weight scale technology, today announced a strategic supply agreement with ...

A survey by 9amHealth found coverage of the GLP-1 class of medication is an “important factor” for 73% of workers when staying at or accepting a new job. That's up from 67% that said the same ...

According to new data from 9amHealth — which provides specialized care for weight management, diabetes, and heart health — 54% of Americans are using or want to use a GLP-1 medication.